Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals

Zdanowski, Wojciech; Markiewicz, Agnieszka; Zdanowska, Natalia; Lipińska, Janina; Waśniewski, Tomasz

doi:10.3390/vaccines10020200

Cited by 7 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We identified 12 studies evaluating adverse effects after maternal covid-19 vaccination 373839404244555871818283. In general, symptoms after covid-19 vaccination are usually mild to moderate and occur within the first three days after vaccination.…”

Section: Covid-19 Vaccinesmentioning

confidence: 99%

Covid-19 vaccination in pregnancy

Badell

Dude

Rasmussen

et al. 2022

BMJ

View full text Add to dashboard Cite

Pregnancy is an independent risk factor for severe covid-19. Vaccination is the best way to reduce the risk for SARS-CoV-2 infection and limit its morbidity and mortality. The current recommendations from the World Health Organization, Centers for Disease Control and Prevention, and professional organizations are for pregnant, postpartum, and lactating women to receive covid-19 vaccination. Pregnancy specific considerations involve potential effects of vaccination on fetal development, placental transfer of antibodies, and safety of maternal vaccination. Although pregnancy was an exclusion criterion in initial clinical trials of covid-19 vaccines, observational data have been rapidly accumulating and thus far confirm that the benefits of vaccination outweigh the potential risks. This review examines the evidence supporting the effectiveness, immunogenicity, placental transfer, side effects, and perinatal outcomes of maternal covid-19 vaccination. Additionally, it describes factors associated with vaccine hesitancy in pregnancy. Overall, studies monitoring people who have received covid-19 vaccines during pregnancy have not identified any pregnancy specific safety concerns. Additional information on non-mRNA vaccines, vaccination early in pregnancy, and longer term outcomes in infants are needed. To collect this information, vaccination during pregnancy must be prioritized in vaccine research.

show abstract

Section: Covid-19 Vaccinesmentioning

confidence: 99%

Covid-19 vaccination in pregnancy

Badell

Dude

Rasmussen

et al. 2022

BMJ

View full text Add to dashboard Cite

show abstract

“…Additionally, three studies were identified through the manual search and website search. Finally, we included 35 studies with 86 datapoints [ 11 , 12 , 20 - 52 ]. The study selection process is presented in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background Understanding the incidence pattern of cutaneous reactions is crucial for promoting COVID-19 vaccination. We aimed to report the global incidence pattern of, and factors associated with common cutaneous reactions related to COVID-19 vaccination in real-world settings. Methods We searched five databases (PubMed, Web of Science, Embase, CNKI, and Wanfang) from inception to May 13, 2022, for studies reporting the incidence of common cutaneous reactions related to COVID-19 vaccines in real-world settings. The outcomes were the systematic skin reactions (rash and urticaria) and the local injection site reactions (pain, swelling, redness, and erythema). We conducted random-effects meta-analyses and explored associated factors using multi-step statistical analyses. Results We included 35 studies and assessed 2 549 968 participants from 23 countries. The pooled incidence of overall systemic skin reactions was 3.8% (95% confidence interval (CI) = 2.4%-5.5%) with short duration (about one week). Specifically, the pooled incidence rates of rash and urticaria were 3.0% (95% CI = 2.1%-3.9%) and 1.1% (95% CI = 0.7%-1.5%), respectively. For overall local injection site reactions, the pooled incidence was 72.4% (95% CI = 65.7%-78.7%) with short duration (1 to 4.5 days). Except for local pain (72.2%, 95% CI = 65.3%-78.5%), other localized reactions had low incidence, including swelling (13.3%, 95% CI = 9.5%-17.7%), redness (11.5%, 95% CI = 5.7%-19.0%), and erythema (5.8%, 95% CI = 0.7%-15.4%). Geographically, different distribution patterns were observed for these reactions. Regarding associated factors, mRNA vaccines showed lower incidence of urticaria ( P < 0.001). Asia population showed higher incidence of urticaria ( P < 0.001). We observed lower incidence rates of overall local injection site reactions and pain among inactivated vaccines ( P < 0.001). We found no significant difference among reactions between the first and the second dose of vaccines. Conclusions We examined the global incidence pattern of common cutaneous reactions related to COVID-19 vaccination and found low incidence and short duration of systemic skin reactions and local injection site reactions (except for pain); discrepancies in these reactions were observed across different vaccine types. The cutaneous side effects related to COVID-19 vaccination do not seem to cause concern. Registration PROSPERO: CRD42021258012.

show abstract

“…[157] We included 134 studies (87% RNA vaccines) published until December 31, 2022. We found more than 20 new studies that our present review evaluating the safety of COVID-19 vaccines during pregnancy [158] , [159] , [160] , [161] , [162] , [163] , [164] , [165] , [166] , [167] , [168] , [169] , [170] , [171] , [172] , [173] , [174] , [175] , [176] , [88] , [177] . Most of studies were conducted in Europe [159] , [160] , [162] , [169] , [170] , [171] , [177] , North America [163] , [168] , [172] , [173] , [175] , [88] and Asia [158] , [161] , [164] , [167] , [174] , [176] .…”

Section: Discussionmentioning

confidence: 99%